Cargando…

Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis

BACKGROUND: Circulating progenitor cells (CPC) contribute to the homeostasis of the vessel wall, and a reduced CPC count predicts cardiovascular morbidity and mortality. We tested the hypothesis that CPC count improves cardiovascular risk stratification and that this is modulated by low-grade inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Fadini, Gian Paolo, Maruyama, Shoichi, Ozaki, Takenori, Taguchi, Akihiko, Meigs, James, Dimmeler, Stefanie, Zeiher, Andreas M., de Kreutzenberg, Saula, Avogaro, Angelo, Nickenig, Georg, Schmidt-Lucke, Caroline, Werner, Nikos
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901328/
https://www.ncbi.nlm.nih.gov/pubmed/20634884
http://dx.doi.org/10.1371/journal.pone.0011488
_version_ 1782183674847952896
author Fadini, Gian Paolo
Maruyama, Shoichi
Ozaki, Takenori
Taguchi, Akihiko
Meigs, James
Dimmeler, Stefanie
Zeiher, Andreas M.
de Kreutzenberg, Saula
Avogaro, Angelo
Nickenig, Georg
Schmidt-Lucke, Caroline
Werner, Nikos
author_facet Fadini, Gian Paolo
Maruyama, Shoichi
Ozaki, Takenori
Taguchi, Akihiko
Meigs, James
Dimmeler, Stefanie
Zeiher, Andreas M.
de Kreutzenberg, Saula
Avogaro, Angelo
Nickenig, Georg
Schmidt-Lucke, Caroline
Werner, Nikos
author_sort Fadini, Gian Paolo
collection PubMed
description BACKGROUND: Circulating progenitor cells (CPC) contribute to the homeostasis of the vessel wall, and a reduced CPC count predicts cardiovascular morbidity and mortality. We tested the hypothesis that CPC count improves cardiovascular risk stratification and that this is modulated by low-grade inflammation. METHODOLOGY/PRINCIPAL FINDINGS: We pooled data from 4 longitudinal studies, including a total of 1,057 patients having CPC determined and major adverse cardiovascular events (MACE) collected. We recorded cardiovascular risk factors and high-sensitive C-reactive protein (hsCRP) level. Risk estimates were derived from Cox proportional hazard analyses. CPC count and/or hsCRP level were added to a reference model including age, sex, cardiovascular risk factors, prevalent CVD, chronic renal failure (CRF) and medications. The sample was composed of high-risk individuals, as 76.3% had prevalent CVD and 31.6% had CRF. There were 331 (31.3%) incident MACE during an average 1.7±1.1 year follow-up time. CPC count was independently associated with incident MACE even after correction for hsCRP. According to C-statistics, models including CPC yielded a non-significant improvement in accuracy of MACE prediction. However, the integrated discrimination improvement index (IDI) showed better performance of models including CPC compared to the reference model and models including hsCRP in identifying MACE. CPC count also yielded significant net reclassification improvements (NRI) for CV death, non-fatal AMI and other CV events. The effect of CPC was independent of hsCRP, but there was a significant more-than-additive interaction between low CPC count and raised hsCRP level in predicting incident MACE. CONCLUSIONS/SIGNIFICANCE: In high risk individuals, a reduced CPC count helps identifying more patients at higher risk of MACE over the short term, especially in combination with a raised hsCRP level.
format Text
id pubmed-2901328
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-29013282010-07-15 Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis Fadini, Gian Paolo Maruyama, Shoichi Ozaki, Takenori Taguchi, Akihiko Meigs, James Dimmeler, Stefanie Zeiher, Andreas M. de Kreutzenberg, Saula Avogaro, Angelo Nickenig, Georg Schmidt-Lucke, Caroline Werner, Nikos PLoS One Research Article BACKGROUND: Circulating progenitor cells (CPC) contribute to the homeostasis of the vessel wall, and a reduced CPC count predicts cardiovascular morbidity and mortality. We tested the hypothesis that CPC count improves cardiovascular risk stratification and that this is modulated by low-grade inflammation. METHODOLOGY/PRINCIPAL FINDINGS: We pooled data from 4 longitudinal studies, including a total of 1,057 patients having CPC determined and major adverse cardiovascular events (MACE) collected. We recorded cardiovascular risk factors and high-sensitive C-reactive protein (hsCRP) level. Risk estimates were derived from Cox proportional hazard analyses. CPC count and/or hsCRP level were added to a reference model including age, sex, cardiovascular risk factors, prevalent CVD, chronic renal failure (CRF) and medications. The sample was composed of high-risk individuals, as 76.3% had prevalent CVD and 31.6% had CRF. There were 331 (31.3%) incident MACE during an average 1.7±1.1 year follow-up time. CPC count was independently associated with incident MACE even after correction for hsCRP. According to C-statistics, models including CPC yielded a non-significant improvement in accuracy of MACE prediction. However, the integrated discrimination improvement index (IDI) showed better performance of models including CPC compared to the reference model and models including hsCRP in identifying MACE. CPC count also yielded significant net reclassification improvements (NRI) for CV death, non-fatal AMI and other CV events. The effect of CPC was independent of hsCRP, but there was a significant more-than-additive interaction between low CPC count and raised hsCRP level in predicting incident MACE. CONCLUSIONS/SIGNIFICANCE: In high risk individuals, a reduced CPC count helps identifying more patients at higher risk of MACE over the short term, especially in combination with a raised hsCRP level. Public Library of Science 2010-07-09 /pmc/articles/PMC2901328/ /pubmed/20634884 http://dx.doi.org/10.1371/journal.pone.0011488 Text en Fadini et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fadini, Gian Paolo
Maruyama, Shoichi
Ozaki, Takenori
Taguchi, Akihiko
Meigs, James
Dimmeler, Stefanie
Zeiher, Andreas M.
de Kreutzenberg, Saula
Avogaro, Angelo
Nickenig, Georg
Schmidt-Lucke, Caroline
Werner, Nikos
Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title_full Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title_fullStr Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title_full_unstemmed Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title_short Circulating Progenitor Cell Count for Cardiovascular Risk Stratification: A Pooled Analysis
title_sort circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901328/
https://www.ncbi.nlm.nih.gov/pubmed/20634884
http://dx.doi.org/10.1371/journal.pone.0011488
work_keys_str_mv AT fadinigianpaolo circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT maruyamashoichi circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT ozakitakenori circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT taguchiakihiko circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT meigsjames circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT dimmelerstefanie circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT zeiherandreasm circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT dekreutzenbergsaula circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT avogaroangelo circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT nickeniggeorg circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT schmidtluckecaroline circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis
AT wernernikos circulatingprogenitorcellcountforcardiovascularriskstratificationapooledanalysis